Vertex Raises 2026 Guidance on Strong Quarter

Vertex Pharmaceuticals ($VRTX) raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion, up from the $13.1 billion to $13.2 billion it forecast last quarter. The lift followed third-quarter revenue of $3.44 billion, up 12% from a year earlier. The quarter also included the close of Vertex's roughly $10 billion acquisition of Crinetics Pharmaceuticals, adding a fourth commercial pillar in rare endocrine diseases.